Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT05523999
Recruiting Observational

Recognition of a Cardiac Arrest Within the EMS

NCT05523999 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2024-06-03
Last updated
2024-12-31

Condition(s) studied

Cardiac Arrest

Investigational drug(s) / intervention(s)

Time elapsed between the taking in charge of the call and the recognition of a cardiac arrest by the MRA

Time elapsed between the taking in charge of the call and the recognition of a cardiac arrest by the MRA: Prospective study within the EMS 95, to evaluate if the maximum delay of 90 seconds between the call to the EMS and the recognition of the cardiac arrest is reached.

Study summary

This study aims to evaluate the average time taken by the Medical Regulation Assistants (MRA) to detect a cardiac arrest during the call to the EMS as well as the factors influencing this delay.

Its main objective is to evaluate the delay, in seconds, between the call being picked up and the recognition of a cardiac arrest by the medical regulation assistant at the EMS 95

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria : \- Any call resulting in the detection of a cardiac arrest during ARM regulation: calls to 15 and calls transmitted by 18 Exclusion Criteria : * Traumatic context * Call involving cardiac arrest already identified as such by the caller or 18 * Call with criteria of proven death * The caller does not speak French, the linguistic elements noted are not usable.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
EMS department - Hospital René Dubos - Pontoise Pontoise France Recruiting

More Hôpital NOVO trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05523999 on ClinicalTrials.gov ↗ ← All trials in France